Nutriband Inc. NTRBW
0.55 USD -1.18 (-68.21%)
Sep 30, 2026, 3:59 PM EDT
0.3414 Day range 1.50
0.175 52-week range 2.99
- YTD
- -65.84%
- 1 year
- -62.84%
- Market cap
- 6.69M
- Revenue (ttm)
- 2.02M
- EPS (ttm)
- -0.505
- YTD return
- -65.84%
- 1-year return
- -62.84%
- Volume
- 46.06K
- Avg volume
- 6.25K
- Open
- 2.61
- Previous close
- 1.73
- Day's range
- 0.3414 – 1.50
- 52-week range
- 0.175 – 2.99
- Beta
- 0.42
No chart data for this range yet.
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.61
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -14.30%
- Free cash flow
- -1.55M
- Total cash
- 8.35M
- Total debt
- 527.92K
- Return on equity
- -60.41%
- Short % of float
- 0.00%
- 50-day average
- 1.51
- 200-day average
- 1.14
Next earnings
Consensus EPS estimate 0.00.
About Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nutriband.com
News
Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274 
Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology 
Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders 
Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis 
Nutriband Inc. (NASDAQ:NTRBW) Short Interest Update 
Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing 
Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit 
Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch 
Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight 
Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
Your note
Sign in to keep a note on NTRBW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Citadel Advisors Llc | 15.55% | 116,591 | 221.52K | Sep 29, 2024 |
| Virtu Financial LLC | 1.49% | 11,154 | 21.19K | Sep 29, 2024 |
| Clear Street LLC | 0.48% | 3,608 | 6.86K | Sep 29, 2024 |
| UBS Group AG | 0.06% | 415 | 788 | Sep 29, 2024 |